CLN3基因在卵巢浆液性囊腺癌中的表达及耐药相关性的研究

CLN3 gene expression in ovarian serous cystadenocarcinoma and drug-resistant correlation research

目的探讨CLN3(青少年神经元腊样质脂褐质沉积症Juvenile,form of neuronalceroid-lipofuscinosis,JNCL,Batten病)基因在卵巢浆液性囊腺癌中的表达特点及其在卵巢癌化疗耐药中的作用。方法采用半定量RT-PCR、Western blot以及免疫组化的方法检测CLN3在卵巢浆液性囊腺癌中的表达,分析其表达与临床病理特征及化疗耐药的相关性。结果 CLN3在卵巢浆液性囊腺癌中的表达高于正常卵巢组织,且临床分期越晚其表达越高(P<0.05),而与肿瘤患者年龄无显著相关性。CLN3在卵巢癌化疗耐药组表达阳性率明显高于化疗敏感组(P<0.05)。结论卵巢癌中CLN3高表达与卵巢癌的发生、发展、浸润和转移有关,与卵巢癌化疗耐药密切相关。CLN3可成为卵巢癌化疗新的基因治疗靶点。

Objective：Explore CLN3 gene expression in ovarian serous cystadenocarcinoma characteristics and its role in ovarian cancer chemotherapy drug resistance. Methods：Using semi-quantitative RT-PCR. Western blot and immunohistochemical method to detect CLN3 expression in ovarian serous cystadenocarcinoma,analyze its expression and the clinical pathology characteristic and the correlation of chemotherapy drug resistance. Results：CLN3 expression in ovarian serous cystadenocarcinoma is higher than normal ovarian tissue and the longer the higher expression and the clinical stages（P﹤0.05）,and there was no significant correlation with tumor patients age. CLN3 expression positive rate in ovarian cancer chemotherapy drug resistance group was obviously higher than that of chemotherapy sensitivity group. Conclusion：CLN3 high expression in ovarian cancer and ovarian cancer occurrence,development,invasion and metastasis,closely associated with ovarian cancer chemotherapy drug resistance. CLN3 can be as a new gene therapy targets ovarian cancer chemotherapy.